AUCKLAND, NZ / ACCESS Newswire / June 29, 2026 / In a digital world where every business, creator, print-on-demand seller, ...
Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...
Matica Biotechnology, Inc. ("Matica Bio"), a viral vector contract development and manufacturing organization (CDMO), is ...
Successful Type B RDEP Meeting confirms FDA alignment on pivotal Phase 3 study designFDA indicates Opus Genetics may submit a BLA based on ...
6d
Modern Data & Knowledge Platforms: The Foundation Every AI Strategy Actually Runs On: SD Times 100
Part of the SD Times 100 2026 series. See the full SD Times 100 2026 list for every category and honoree. Every conversation ...
Check Point researchers have identified a new cyber adversary targeting Israeli government and IT businesses, tracked as ...
Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia June 29, 2026 2:00 PM ...
LLVM powers the core development tools, operating systems, and most applications at Apple Computer, where it long ago ...
The 53rd annual conference presents peer-reviewed breakthroughs in simulation, vectorization, and physics modeling across ...
Kriya Therapeutics, Inc. ("Kriya"), a biotechnology company developing durable medicines for chronic diseases, today announced it has been selected by the U.S. Food and Drug Administration (FDA) to ...
In 2025 and 2026, several independent sources have highlighted the same trend: Prompt injection remains one of the most ...
Phase 1/2a trial of MP0712, 212Pb-based DLL3-targeted Radio-DARPin co-developed with Orano Med: Dosing ongoing in first patients; initial data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results